Headlines

Biotech Firm Receives $7.5M Grant for Glaucoma Research

The money comes from the German state of Saxony.

Published

4 years ago

November 6, 2019

NEW YORK — Q BioMed Inc., a commercial stage biotech company, announced that its technology partner, Mannin, has received a $7.5M grant from the German state of Saxony.

The objective of the grant is to fund the development of novel pharmaceuticals and biologic treatments for glaucoma.

INVISION Podcast

Bringing Independent ECPs Into the 21st Century With the Technology Solutions a Modern Eyecare Business Needs

INVISION Podcast

The Making of Bespoke Eyewear, An Acetate Kitchen and Collecting Famous People’s Heads

INVISION Podcast

Fierce Independence, Southern Hospitality and Little Side of Unsolved Murder?

The approval of the grant means that Q BioMed and Mannin “can significantly accelerate the development of these therapeutics,” according to a press release.

Denis Corin, CEO of Q BioMed, said, “We are thrilled that we will be able to speed the development of these promising therapeutics and bring new innovation to glaucoma patients as soon as possible. Our partnership with Mannin and now, the government of Saxony is important to the advancement of this unique drug platform and we look forward to supporting the build-out of the Mannin European headquarters in Leipzig.”

Mannin is a research-stage biotechnology company focused on the discovery, development and commercialization of therapeutics for vascular diseases. It was founded in July 2012 and is led by President and CEO Dr. George Nikopoulos. Q BioMed and Mannin have been partners since 2015.

George Nikopoulos, president and CEO of Mannin, stated, “We are very encouraged by the confidence and enthusiasm the government of Saxony has shown in our research, and we are committed to making accelerated progress through their investment.”

Mannin is leveraging two distinct modes of action to reduce the intraocular pressure that causes glaucoma, utilizing different routes of administration and dosing regimens. Mannin is currently working on the preclinical development of a small molecule pharmaceutical eye-drop as well as a novel recombinant protein injectable biologic. This approach “increases the probability of success of developing a new therapy that is optimized for the needs of glaucoma patients,” according to the release. Additionally, Mannin is exploring other therapeutic opportunities using these molecules for vascular diseases.

Q BioMed and Mannin intend to announce further details regarding the research program later this year.

Crizal® Sapphire™ HR: Invisible Shield of Protection

Your patients’ main concerns of anti-glare, scratch resistance, and easiness to clean are covered. Crizal Sapphire HR, the latest and most advanced product in the Crizal No-Glare range, is now widely available across lab networks and through all major managed vision care providers. Crizal Sapphire HR is available with Essilor’s advanced lens designs such as Varilux® progressive lenses and Eyezen® enhanced single vision lenses. Click here to learn more. *External laboratory tests and internal technical tests – 2020. Compared to the competitor most known lens-brands by consumers (2019 external brand tracking in 11 countries). The word ’overall’ refers to anti-reflective coatings important criteria, ranked through an external quantitative consumer study – 2019.